Cytek Biosciences, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCytek Biosciences is a cell analysis company commercializing full spectrum profiling flow cytometry instruments, reagents, and software for research and clinical use.
What they do
Cytek designs and sells full spectrum flow cytometers (Cytek Aurora, Northern Lights, Aurora Evo, Aurora CS sorter) and reagents, supported by proprietary SpectroFlo software and service. It manufactures in Fremont, California; Wuxi, China; and Singapore, selling directly in North America, Europe, China, and parts of Asia-Pacific, and through distributors elsewhere. The platform enables high-dimensional cell analysis with up to 50 colors in a single tube, targeting applications in oncology, immunology, and infectious disease research.
Revenue drivers
- Instruments — Core product sales of Aurora, Northern Lights, Aurora Evo, and Aurora CS systems; strong double-digit growth in U.S. and China in Q2 2026; subject to quarterly fluctuations due to long sales cycles.
- Recurring revenue (service and reagents) — Totaled $18.5 million in Q2 2026; on a trailing-12-month basis represented 35% of total revenue, up from 32% a year earlier.
- Direct vs. distributor sales — Direct sales were 69% of revenue in Q2 2026, distributors 31%; direct model focuses on North America, Europe, China, and parts of Asia-Pacific.
Recent performance
Total revenue for Q2 2026 was $48.1 million, up 6% year-over-year, with net loss of $12.2 million versus a $5.6 million loss in Q2 2025. GAAP gross margin was 59%, up from 52% a year ago, including a one-time tariff refund; excluding that refund, adjusted gross margin was 56%. Operating expenses rose 15% to $39.7 million, driven by litigation, severance, and personnel costs. Cash, cash equivalents, and marketable securities totaled $262.0 million at June 30, 2026.
Strategy
Management emphasizes accelerating adoption of instrument platforms, including newly launched products, expanding the recurring revenue base, and extending technology leadership. The company is investing in research and development ($9.7 million in Q2 2026) and in sales and marketing globally. Recent product launches include the Cytek Borealis 7-laser cytometer and Aurora Evo configurations with expanded automation. The company plans to continue hiring commercial staff and expanding reagent offerings and panel design capabilities.
Risks
- Concentration in limited product lines — Revenue is primarily generated from a few core instrument models (Aurora, Northern Lights, Aurora Evo, Aurora CS), making results sensitive to demand for these specific products.
- Single-source supplier reliance — The company depends on single-source and sole-source suppliers for certain components, and disruptions could delay manufacturing or increase costs.
- Quarterly revenue volatility — Instruments have a substantial sales cycle and are prone to quarterly fluctuations, which can cause unpredictable financial results.
- Escalating operating expenses — Operating expenses increased 15% in Q2 2026, with litigation-related expenses and severance costs driving G&A up 24%, pressuring near-term profitability.
Outlook
Cytek updated its full-year 2026 revenue guidance to $207 million to $212 million, raising the midpoint by $1 million. Management expects continued adoption of new instruments, growth in recurring revenue, and benefits from investments in products and operations. The outlook assumes no change in current foreign currency exchange rates.